Dr. Richard Isaacson was featured in The Wall Street Journal discussing the growing interest in GLP-1 medications such as Ozempic and Wegovy as researchers explore their potential benefits beyond weight loss. The article examines emerging evidence suggesting these medications may one day play a role in promoting healthier aging, while emphasizing that more research is needed to understand their long-term effects on age-related conditions, including Alzheimer’s disease.

Dr. Isaacson shared his perspective on the promise of GLP-1 therapies as part of a personalized approach to healthy aging, noting that while the early findings are encouraging, these medications should be considered alongside evidence-based lifestyle strategies and individualized medical care as research continues to evolve.

Read the full Wall Street Journal article to learn more about the emerging science behind GLP-1 medications and their potential role in supporting brain health and longevity.